Dbb-06 Pro Hemodialysis Delivery System Dbb-06 Pro
Nikkiso
FDA Clearance Information
The dbb-06 pro hemodialysis delivery system by Nikkiso was cleared via the FDA 510(k) pathway on May 15, 2025. It is classified as a Class 2 device under product code KDI.
What It Is
FDA-Cleared Indications
- For use in hemodialysis treatment to provide extracorporeal blood purification.
- For removal of metabolic waste products and excess fluid from the blood of patients with inadequate kidney function.
- For use with compatible hemodialysis equipment, dialyzers, blood tubing, dialysate and water systems according to the manufacturer's labeling.
Clinical Applications
- Maintenance hemodialysis for patients with end-stage kidney disease.
- Hemodialysis for patients with acute kidney injury when renal replacement therapy is clinically indicated.
- Delivery and monitoring of dialysate during intermittent hemodialysis.
- Support of extracorporeal blood purification in a dialysis center or other appropriately equipped clinical setting.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The system must be used with compatible dialyzers, blood tubing sets, dialysate concentrates, treated water and other accessories specified in the manufacturer's instructions.
- Treatment requires vascular access, such as an arteriovenous fistula, arteriovenous graft or dialysis catheter; the access is not part of the delivery system.
- The device is operated by trained dialysis personnel who monitor blood flow, dialysate flow, pressures, fluid removal and treatment alarms.
- MRI compatibility should not be assumed. Because the system contains electrical and mechanical components, it should remain outside the MRI environment unless the manufacturer provides specific MR labeling.
- Use is limited by standard hemodialysis contraindications and precautions, including inability to establish safe vascular access, severe hemodynamic instability or unsafe fluid and electrolyte conditions.
Frequently Asked Questions
What are the clinical indications for dbb-06 pro?
The dbb-06 pro is indicated for use in patients requiring hemodialysis, such as those with chronic kidney disease or acute kidney injury.
What outcomes have been reported in clinical studies?
Studies report general improvements in dialysis efficiency, but specific outcomes for the dbb-06 pro are not detailed.
What complications have been reported?
Reported complications include general hemodialysis risks like vascular access issues and infection, but specific data for the dbb-06 pro is not provided.